JP2021505541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505541A5 JP2021505541A5 JP2020529313A JP2020529313A JP2021505541A5 JP 2021505541 A5 JP2021505541 A5 JP 2021505541A5 JP 2020529313 A JP2020529313 A JP 2020529313A JP 2020529313 A JP2020529313 A JP 2020529313A JP 2021505541 A5 JP2021505541 A5 JP 2021505541A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- isomer
- hydrate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 O=C(*1)C=CC1=O Chemical compound O=C(*1)C=CC1=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592721P | 2017-11-30 | 2017-11-30 | |
| US62/592,721 | 2017-11-30 | ||
| PCT/US2018/063376 WO2019108974A1 (en) | 2017-11-30 | 2018-11-30 | Albumin-binding prodrugs of auristatin e derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505541A JP2021505541A (ja) | 2021-02-18 |
| JP2021505541A5 true JP2021505541A5 (https=) | 2022-01-11 |
| JP7359449B2 JP7359449B2 (ja) | 2023-10-11 |
Family
ID=64744961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529313A Active JP7359449B2 (ja) | 2017-11-30 | 2018-11-30 | オーリスタチンｅ誘導体のアルブミン結合プロドラッグ |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11377473B2 (https=) |
| EP (2) | EP4344747A3 (https=) |
| JP (1) | JP7359449B2 (https=) |
| KR (1) | KR20200118408A (https=) |
| CN (2) | CN111712511B (https=) |
| AU (1) | AU2018375787B2 (https=) |
| BR (1) | BR112020009836A2 (https=) |
| DK (1) | DK3717503T3 (https=) |
| ES (1) | ES2970618T3 (https=) |
| IL (1) | IL274919B2 (https=) |
| MX (1) | MX2020005658A (https=) |
| NZ (1) | NZ764948A (https=) |
| PT (1) | PT3717503T (https=) |
| WO (1) | WO2019108974A1 (https=) |
| ZA (1) | ZA202002951B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6948708B2 (ja) | 2015-06-19 | 2021-10-13 | センチュリオン バイオファーマ コーポレイション | 薬物制御放出のための送達系 |
| AU2018375788A1 (en) | 2017-11-30 | 2020-07-09 | Ladrx Corporation | Maytansinoid-based drug delivery systems |
| CN113321698B (zh) * | 2020-02-28 | 2022-08-23 | 国家纳米科学中心 | 一种单甲基澳瑞他汀e前药及其制备方法和应用 |
| SI4153242T1 (sl) * | 2020-05-19 | 2024-07-31 | Les Laboratoires Servier | Para-amino-benzilni linkerji, postopek za njihovo pripravo in njihova uporaba v konjugatih |
| CN115969986A (zh) * | 2022-12-30 | 2023-04-18 | 上海药明生物技术有限公司 | 羟丙基β环糊精稳定MMAE类抗体药物偶联物制剂的应用 |
| WO2024230301A1 (zh) * | 2023-05-09 | 2024-11-14 | 诺灵生物医药科技(北京)有限公司 | 一种抗体偶联药物及其用途 |
| CN116813569B (zh) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | 一种抗癌药中间体的制备方法和抗癌药的制备方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125704A (en) | 1977-09-14 | 1978-11-14 | Sri International | Phenyl-substituted rubidazone analogs |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| NZ547370A (en) | 2003-12-04 | 2010-09-30 | Amr Technology Inc | Vinca derivatives |
| CN101490087B (zh) * | 2006-05-30 | 2013-11-06 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
| CN101743020A (zh) | 2007-05-16 | 2010-06-16 | Ktb肿瘤研究有限责任公司 | 低粘度蒽环制剂 |
| EP2289558A1 (en) | 2009-08-25 | 2011-03-02 | KTB Tumorforschungsgesellschaft mbH | Bisphosphonate-prodrugs |
| EP2630971B8 (en) | 2012-02-21 | 2017-12-13 | Vergell Medical S.A. | Combinations of albumin-based drug delivery systems |
| US20140221429A1 (en) | 2013-02-04 | 2014-08-07 | Saud Ibrahim Al-Resayes | Heterocyclic schiff's bases as novel and new antiglycation agents |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| JP6908964B2 (ja) * | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| FR3017298B1 (fr) | 2014-02-07 | 2016-03-04 | Centre Nat Rech Scient | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
| AU2015329625B2 (en) * | 2014-10-10 | 2018-04-05 | Pfizer Inc. | Synergistic auristatin combinations |
| WO2016205378A1 (en) | 2015-06-15 | 2016-12-22 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
| JP6948708B2 (ja) | 2015-06-19 | 2021-10-13 | センチュリオン バイオファーマ コーポレイション | 薬物制御放出のための送達系 |
| AU2018375788A1 (en) | 2017-11-30 | 2020-07-09 | Ladrx Corporation | Maytansinoid-based drug delivery systems |
| US11632502B2 (en) | 2021-09-10 | 2023-04-18 | Pixart Imaging Inc. | Optical sensor cancelling image flicker |
-
2018
- 2018-11-30 EP EP23207873.3A patent/EP4344747A3/en not_active Withdrawn
- 2018-11-30 PT PT188222129T patent/PT3717503T/pt unknown
- 2018-11-30 KR KR1020207018898A patent/KR20200118408A/ko active Pending
- 2018-11-30 EP EP18822212.9A patent/EP3717503B1/en active Active
- 2018-11-30 AU AU2018375787A patent/AU2018375787B2/en active Active
- 2018-11-30 IL IL274919A patent/IL274919B2/en unknown
- 2018-11-30 ES ES18822212T patent/ES2970618T3/es active Active
- 2018-11-30 DK DK18822212.9T patent/DK3717503T3/da active
- 2018-11-30 MX MX2020005658A patent/MX2020005658A/es unknown
- 2018-11-30 US US16/768,436 patent/US11377473B2/en active Active
- 2018-11-30 BR BR112020009836-1A patent/BR112020009836A2/pt not_active Application Discontinuation
- 2018-11-30 WO PCT/US2018/063376 patent/WO2019108974A1/en not_active Ceased
- 2018-11-30 NZ NZ764948A patent/NZ764948A/en unknown
- 2018-11-30 JP JP2020529313A patent/JP7359449B2/ja active Active
- 2018-11-30 CN CN201880088118.0A patent/CN111712511B/zh active Active
- 2018-11-30 CN CN202410777137.1A patent/CN118852324A/zh active Pending
-
2020
- 2020-05-20 ZA ZA2020/02951A patent/ZA202002951B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505541A5 (https=) | ||
| AU2009308511B2 (en) | Transition metal complexes of a bis[thiohydrazide amide] compound | |
| JP7028809B2 (ja) | コルテキソロン１７α－バレレートを含む腫瘍治療に用いるための組成物 | |
| TW200418449A (en) | Treatment for cancers | |
| IL274919B1 (en) | Albumin-binding prodrugs of auristatin E derivatives | |
| JP2018529780A (ja) | グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法 | |
| JP7193591B2 (ja) | 化学療法の改善 | |
| JP2016519107A (ja) | Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー | |
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| EP3542827A1 (en) | Emulsion composition for chemoembolization and method for producing same | |
| JP2021505551A5 (https=) | ||
| CN101484443A (zh) | 放射线治疗增强剂 | |
| AU2017235350B2 (en) | Combination therapy for proliferative diseases | |
| JP2018530568A5 (https=) | ||
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| WO2022051491A1 (en) | Pharmaceutical compositions of tetracyclic quinolone analogs and their salts | |
| JP2005510471A (ja) | 減少した毒性のシスプラチン製剤及びそれを使用する方法 | |
| WO2016205299A1 (en) | New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol | |
| JP2021532123A5 (https=) | ||
| AU2002334595A1 (en) | Reduced toxicity cisplatin formulations and methods for using the same | |
| CN118846070A (zh) | 一种用于治疗kras突变肿瘤的药物组合物及应用 | |
| RU2020121456A (ru) | Системы доставки лекарств на основе майтанзиноида | |
| WO2020229685A1 (en) | Combination therapy for proliferative conditions | |
| US20090118340A1 (en) | Method for inhibiting and/or preventing formation of cancer metastases and seconddary malignant cancers | |
| JP2001072606A (ja) | 高分子型癌転移・再発予防剤 |